Fig 3.

Evaluation of vessel density within the ischemic, gangrenous footpads of the murine ligated hindlimb with E-selectin/adeno-associated virus (AAV) vs control (LacZ/AAV) gene therapy. Treatment with E-selectin/AAV gene therapy resulted in increased footpad vessel density. A, Representative images showing DiI perfusion capillary density was improved in treatment vs control groups on postoperative day (POD) 14. B, Quantification of capillary density in ischemic, gangrene footpads of both E-selectin/AAV treatment (n = 5) and LacZ/AAV treatment (n = 5); E-selectin/AAV–treated ischemic footpad capillary density was 44 capillaries per myofibril cross-sectional area, and LacZ/AAV–treated footpad capillary density was 22 capillaries per myofibril cross-sectional area (∗P < .001, two-tailed Student's t test).